What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push
Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.
You may also be interested in...
Dr Reddy’s CEO: We’re In ‘Great Dialogue’ With The Innovation Industry In China
Dr Reddy’s is collaborating with innovator firms in China, Israel and the US largely in areas of unmet need, propelling its “Horizon-2” strategy that encompasses segments like biologics and cell and gene therapy, digital services and immuno-oncology NCEs, among others.
Will Liraglutide Make It To WHO's Essential Medicines List?
Forthcoming review of WHO’s Model List of Essential Medicines is expected to consider glucagon-like peptide 1 receptor agonists such as Novo Nordisk’s liraglutide and also CAR-T therapies, among others. Scrip discusses with experts the prospects of their inclusion and the wider opportunities for industry.
Immuneel COO On Benchmarking The Firm’s CAR-T Against Mature, Global Data Sets
Immuneel’s COO, Dr Arun Anand, talks to Scrip about how things are shaping for the Indian start-up’s autologous CD19 directed CAR-T cell therapy and the ‘journey to be traversed’ on the pricing front. He believes India could potentially see cell therapies being commercialized in the next 12 to 18 months.